HR Execs on the Move

Delfi Diagnostics

www.delfidiagnostics.com

 
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Jessica Meng
Chief Commercial Officer Profile
Doug Schenkel
Chief Financial Officer Profile
Akash Patel
Director, Financial Planning and Analysis Profile
Monique Cadle
Vice President of People Profile
Victor Velculescu
Founder and Chief Executive Officer Profile

Similar Companies

Preferred Health Partners

Preferred Health Partners is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cultiv8 Hemp Solutions

Cultiv8 Hemp Solutions, Inc. specializes in the growth and harvest of industrial hemp. We manufacture biodegradable paper and plastic alternatives, as well as biofuel, protien, and biomass.

Specialty Flooring Systems Inc

Specialty Flooring Systems Inc is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

ImmunoPrecise Antibodies

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.